Evidence map›Paper›PMID 42517630›Full record

ArticleJournal of virology2026

ViralMap: predicting features in viral proteins from primary sequence.

Shrish Dwivedi, Shaunak Kar, Andrew P Horton, Jimmy D Gollihar

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shrish DwivediSystems, Synthetic, and Physical Biology, Rice University, Houston, Texas, USA.ORCID 0009-0006-6069-8270
Shaunak KarDepartment of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0003-3354-1789
Andrew P HortonDepartment of Pathology & Genomic Medicine, Antibody Discovery and Accelerated Protein Therapeutics, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-0272-4411
Jimmy D GolliharSystems, Synthetic, and Physical Biology, Rice University, Houston, Texas, USA.ORCID 0000-0003-3957-2092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modern viral vaccines are designed to elicit an immune response against viral proteins that mediate infection, making those proteins important targets for characterization and engineering. To improve vaccine efficacy, the proteins often require changes to specific residues or domains to enhance immunogenicity and induce a protective response. These engineering strategies vary significantly across viruses, making comprehensive and accurate protein sequence annotation a crucial step for guiding vaccine design. The growing risk of novel pathogen emergence and initiatives such as the CEPI 100 Days Mission to rapidly counter "Disease X" threats heighten the need for tools that can convert viral protein sequences from newly characterized genomes or emerging variants into the annotation profiles required for antigen engineering. To address this, we developed ViralMap, a multi-label annotation model tailored for eukaryotic viral proteins. By leveraging ESM-2 language model representations, ViralMap simultaneously predicts 10 distinct annotation classes spanning domain topology and localization, post-translational modifications, and structural features directly from primary sequences. The model achieves a residue-level precision-recall area under the curve (PR-AUC) of 0.75 or greater for 7 of the 10 classes, with performance competitive with established tools across the eight benchmarked classes. Case studies on complex glycoproteins from SARS-CoV-2, HIV-1, Nipah virus, and Lassa virus demonstrate the model's ability to predict detailed residue-level annotation profiles, including for proteins from viral families not seen during training. By providing a unified, sequence-based framework for multi-label annotation, ViralMap offers a practical bridge from raw viral protein sequences to the annotation profiles required for antigen engineering.IMPORTANCEThe rapid characterization of viral proteins is critical for developing vaccines against emerging pathogens. When a new strain or virus is identified, researchers need to efficiently identify key features of these proteins to guide vaccine design. Currently, obtaining such features requires running multiple computational tools, which are generally not specialized for viruses that affect humans. ViralMap is a deep learning model that addresses this gap by predicting ten functionally relevant protein annotations simultaneously from sequence alone. Trained specifically on eukaryotic viral proteins, ViralMap aims to support the early stages of vaccine engineering for pandemic preparedness efforts.

Indexed as

Viral ProteinsAmino Acid SequenceComputational BiologyHumansMolecular Sequence AnnotationPrediction AlgorithmsViral VaccinesViral ProteinsViral Vaccinesannotationdeep learningprotein language modelviral glycoproteins

Identifiers

PMID42517630
PMCPMC13483385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.